News

The acquisition is expected to be done for around $175m which will include all outstanding shares and outstanding options. Allied CEO Sandy Young said after an examination of

Alpharadin, a highly targeted alpha-pharmaceutical, currently under clinical evaluation, is intended to improve survival in patients suffering from bone metastases from advanced cancer. Algeta has chosen Onet for

Currently under preclinical development, FabOvar is intended as an treatment for ovarian carcinoma. AAA CEO Stefano Buono said in previous studies FabOvar is an evolution of a previous

Clopidogrel tablets USP are indicated for the treatment for acute coronary syndrome, recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Sun Pharma‘s clopidogrel tablets USP,

Under the amended terms, AbD Serotec has given license to MorphoSys’ HuCAL GOLD technology to Merck for vaccine research. The deal also allows Merck with an option to

Medidata CTMS is expected to help in the reduction of time and effort that is required for tracking key milestones and operational metrics throughout their clinical studies and

Amgen‘s adjusted net income was $1.28m, compared to $1.33m for the same period in the prior year. The company has posted adjusted operating income of $1.47m for the

Under the contract, RaQualia has licensed the development, manufacturing and commercialization rights of 5-HT4 Partial Agonist (RQ-00000010) to CJ in India, Taiwan, Korea and South Asia. As per

Prevnar 13 is indicated for active immunization for the prevention of pneumococcal disease in adult patients aged 50 and older. The FDA has extended the review period till